ARPO - エアピオ・ファ―マシュ―ティカルズ (Aerpio Pharmaceuticals Inc.) エアピオ・ファ―マシュ―ティカルズ

 ARPOのチャート


 ARPOの企業情報

symbol ARPO
会社名 Aerpio Pharmaceuticals Inc (エアピオ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14 2017 the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14 2017 the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.   エアピオ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に眼疾患の治療薬の開発に注力する。主要パイプラインのAKB-9778は、血管透過性制御に関わるTie2シグナル伝達経路により糖尿病網膜症の治療に有効。また、加齢黄斑変性症や糖尿病性黄斑浮腫の治療薬ARP-1536や、炎症性腸疾患のためのAKB-4924がある。本社所在地はオハイオ州シンシナティ。   Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.
本社所在地 9987 Carver Road Cincinnati OH 45242 USA
代表者氏名
代表者役職名
電話番号 +1 513-985-1920
設立年月日 39387
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 25人
url www.aerpio.com
nasdaq_url https://www.nasdaq.com/symbol/arpo
adr_tso
EBITDA EBITDA(百万ドル) -24.51039
終値(lastsale) 3.05
時価総額(marketcap) 123768563.85
時価総額 時価総額(百万ドル) 113.62360
売上高 売上高(百万ドル) 1.33333
企業価値(EV) 企業価値(EV)(百万ドル) 44.84039
当期純利益 当期純利益(百万ドル) -24.30012
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aerpio Pharmaceuticals Inc revenues increased from $0K to $1.3M. Net loss applicable to common stockholders increased 17% to $13.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 54% to $8.1M (expense).

 ARPOのテクニカル分析


 ARPOのニュース

   Lifshitz Law Firm, P.C. Announces Investigation of ARPO, CNBKA, CHAQ, DSSI, INSW, FORE, FTIV, ONB, FMBI, and GRA  2021/06/11 22:02:00 PR Newswire
NEW YORK, June 11, 2021 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ARPO with Aadi Bioscience, Inc. If you are an investor, and would like additional
   NOTICE IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Aerpio Pharmaceuticals Inc (NASDAQ ARPO), MMA Capital Holdings (NASDAQ MMAC), Cimarex Energy Co. (NYSE XEC)  2021/05/28 01:03:00 Oil & Gas 360
NOTICE IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Aerpio Pharmaceuticals Inc (NASDAQ ARPO), MMA Capital Holdings (NASDAQ MMAC), Cimarex Energy Co. (NYSE XEC) NOTICE IMPORTANT SHAREHOLDER The post NOTICE IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Aerpio Pharmaceuticals Inc (NASDAQ ARPO), MMA Capital Holdings (NASDAQ MMAC), Cimarex Energy Co. (NYSE XEC) appeared first on Oil & Gas 360 .
   SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Aerpio Pharmaceuticals, Inc. Merger  2021/05/27 16:13:00 GlobeNewswire
WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Aerpio Pharmaceuticals, Inc. (Aerpio) (NASDAQ GS: ARPO ) regarding possible breaches of fiduciary duties and other violations of law related to Aerpios agreement to merge with Aadi Bioscience, Inc.
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aerpio Pharmaceuticals, Inc. - ARPO  2021/05/22 01:00:00 Benzinga
NEW YORK , May 21, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Aerpio Pharmaceuticals, Inc. ("ARPO" or the "Company") ( ARPO ) relating to its proposed merger with Aadi Bioscience, Inc. Under the terms of the agreement, ARPO shareholders are expected to own 14.7% of the combined company after the closing of the concurrent PIPE financing transaction. The investigation focuses on whether Aerpio Pharmaceuticals, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued. Click here for more information: https://www.monteverdelaw.com/case/aerpio-pharmaceuticals-inc . It is free and there is no cost Full story available on Benzinga.
   AERPIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerpio Pharmaceuticals, Inc. - ARPO  2021/05/21 01:43:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Aerpio Pharmaceuticals, Inc. (the Company) (NasdaqGS: ARPO) with Aadi Bioscience, Inc. pursuant to which Aerpio shareholders will own approximately 14.7% of the combined company following the closing of the concurrent PIPE financing. KSF is seeking to determine whether the merger and the process that led t
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10  2020/11/05 21:01:00 GlobeNewswire
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing…
   Diabetic Nephropathy Market SWOT Analysis by Key Players Daiichi Sankyo, Aerpio Pharmaceuticals, Aibios, Algomedix  2020/09/28 05:21:59 OpenPR
Latest document on 'Diabetic Nephropathy - Pipeline Review, H2 2020' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis includes countries like USA, Germany, China, France, Japan,
   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12  2020/08/10 12:00:00 GlobeNewswire
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10  2020/11/05 21:01:00 GlobeNewswire
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing…
   Diabetic Nephropathy Market SWOT Analysis by Key Players Daiichi Sankyo, Aerpio Pharmaceuticals, Aibios, Algomedix  2020/09/28 05:21:59 OpenPR
Latest document on 'Diabetic Nephropathy - Pipeline Review, H2 2020' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis includes countries like USA, Germany, China, France, Japan,
   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12  2020/08/10 12:00:00 GlobeNewswire
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エアピオ・ファ―マシュ―ティカルズ ARPO Aerpio Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)